Elicio Therapeutics reports developments as a clinical-stage biotechnology company developing cancer immunotherapies. Company news centers on its proprietary Amphiphile, or AMP, technology, the ELI-002 program, and immunotherapy work for mKRAS-positive cancers including pancreatic ductal adenocarcinoma, colorectal cancer, lung cancer, and other KRAS-driven tumors.
Recurring updates also include clinical and regulatory disclosures, operating and financial results, healthcare-conference presentations, shareholder voting and governance matters, capital-structure actions, and Nasdaq inducement stock option grants under the company’s 2024 Inducement Incentive Award Plan.
Elicio Therapeutics (Nasdaq: ELTX) reported three metastatic mKRAS pancreatic cancer patients who progressed on ELI-002 7P in Phase 2 AMPLIFY-7P and later achieved 100% confirmed complete radiographic and metabolic responses after nivolumab-based therapy, with CA19-9 normalization and persistent mKRAS-specific T cells.
According to Elicio, these preliminary observations support evaluating ELI-002 7P with checkpoint inhibition. Subject to funding, the company plans a Phase 1 first-line metastatic PDAC study using gemcitabine/nab-paclitaxel plus anti–PD-1, designed for rapid clinical activity assessment.
Elicio Therapeutics (Nasdaq: ELTX) reported Phase 2 AMPLIFY-7P results in adjuvant mKRAS-driven pancreatic cancer. The study did not meet its primary DFS endpoint in the intent-to-treat population. Post-hoc analyses showed improved DFS in R0 resected patients (HR 0.65, p=0.048) and strong mKRAS-specific T cell correlations (HR 0.22, p<0.0001). ELI-002 7P showed a favorable safety profile with no treatment-related discontinuations or deaths. Guided by these data, Elicio plans a Phase 3 trial focused on R0 patients with extended dosing, subject to financing. The company expects existing cash to fund operations into Q4 2026.
Elicio Therapeutics (Nasdaq: ELTX) reported preclinical data in Science Advances on its lymph node-targeted AMP-DNA adjuvant platform. Studies in mice and non-human primates showed robust, polyfunctional CD8+ and CD4+ T cell responses, durable immune memory for at least nine months, and high neutralizing antibody titers.
AMP-DNA outperformed clinical and commercial benchmark adjuvants, enabled precise lymph node delivery, and drove immune activation through TBK1/IFN-I signaling, expanding Elicio’s AMP immunomodulator portfolio alongside AMP-CpG (ELI-004) for potential next-generation oncology and infectious disease immunotherapies.
Elicio Therapeutics (Nasdaq: ELTX) reported Q1 2026 results and clinical updates. The Phase 2 AMPLIFY-7P primary disease-free survival analysis of ELI-002 7P in post-resection mKRAS PDAC is expected mid-2026, with fewer progressions and deaths than projected.
Q1 R&D was $6.8M, G&A $3.8M, net loss $11.8M ($0.65/share). Cash was $14.9M on March 31, plus $13.0M raised via ATM, supporting operations into Q4 2026.
Elicio Therapeutics (Nasdaq: ELTX) will present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 12:20 PM ET.
Presenters include CEO Robert Connelly, CMO Christopher Haqq, CSO Pete DeMuth, and CSFO Preetam Shah. A live webcast and 90-day replay are available via the company’s Events page. 1×1 meetings are arranged through Bank of America representatives.
Elicio Therapeutics (Nasdaq: ELTX) announced on April 16, 2026 that it granted 21,210 inducement stock options to a new employee, approved by the Compensation Committee under the 2024 Inducement Incentive Award Plan.
The options have a $11.78 per-share exercise price (Nasdaq closing price on April 15, 2026) and vest over four years: 25% on the first anniversary of employment, then monthly thereafter, subject to continued service and Nasdaq Listing Rule 5635(c)(4).
Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 1,600 inducement stock options on March 16, 2026, to a newly hired employee under the 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a strike price of $12.16 (Nasdaq closing price on March 16, 2026) and vest over four years with 25% vesting after one year and monthly ratable vesting thereafter, subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) reported 2025 results and clinical updates on March 12, 2026. The company expects an event-driven primary DFS analysis in 1H 2026 from the randomized Phase 2 AMPLIFY-7P trial in resected mKRAS PDAC and remains blinded to efficacy outcomes.
Notable 2025 financials: R&D $24.9M, G&A $12.8M, net loss $39.6M, and $18.6M cash with runway into Q3 2026; antigen spreading and T-cell durability were reported in December 2025.
Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company presentation is scheduled for March 4, 2026 at 1:10 PM ET.
According to Elicio, a live webcast and a 90-day replay will be available on the company Events page for investors who cannot attend in person.
Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 30,300 inducement stock options on February 17, 2026, to a newly hired employee under its 2024 Inducement Incentive Award Plan.
The options have an exercise price of $8.59 per share (Nasdaq close on Feb 17, 2026) and vest over four years with 25% vesting after one year and monthly vesting thereafter, subject to continued service.